GENVULT Trademark

Trademark Overview

On Thursday, September 3, 2015, a trademark application was filed for GENVULT with the United States Patent and Trademark Office. The USPTO has given the GENVULT trademark a serial number of 86746244. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 26, 2019. This trademark is owned by Pfizer Inc.. The GENVULT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, inflammatory, menopausal, metabolic, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, and urological diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use, excluding vaccines for the treatment or prevention of HIV/AIDS, infectious diseases, and viral or immune system related disorders or diseases
genvult

General Information

Serial Number86746244
Word MarkGENVULT
Filing DateThursday, September 3, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 26, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 26, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, inflammatory, menopausal, metabolic, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, and urological diseases and disorders; pharmaceutical preparations for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations for use in hematology; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations, smoking cessation preparations, and tissue repair preparations; vaccines for human use, excluding vaccines for the treatment or prevention of HIV/AIDS, infectious diseases, and viral or immune system related disorders or diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 8, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, August 26, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 26, 2019ABANDONMENT - NO USE STATEMENT FILED
Wednesday, December 19, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 18, 2018EXTENSION 5 GRANTED
Monday, December 10, 2018EXTENSION 5 FILED
Tuesday, December 18, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 10, 2018TEAS EXTENSION RECEIVED
Thursday, June 14, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 12, 2018EXTENSION 4 GRANTED
Tuesday, June 12, 2018EXTENSION 4 FILED
Tuesday, June 12, 2018TEAS EXTENSION RECEIVED
Tuesday, December 12, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 8, 2017EXTENSION 3 GRANTED
Friday, December 8, 2017EXTENSION 3 FILED
Friday, December 8, 2017TEAS EXTENSION RECEIVED
Friday, June 23, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 21, 2017EXTENSION 2 GRANTED
Wednesday, June 21, 2017EXTENSION 2 FILED
Wednesday, June 21, 2017TEAS EXTENSION RECEIVED
Saturday, December 17, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 15, 2016EXTENSION 1 GRANTED
Thursday, December 15, 2016EXTENSION 1 FILED
Thursday, December 15, 2016TEAS EXTENSION RECEIVED
Tuesday, July 26, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, June 10, 2016EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Thursday, June 2, 2016CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Wednesday, May 25, 2016ASSIGNED TO PETITION STAFF
Thursday, May 12, 2016TEAS POST PUBLICATION AMENDMENT RECEIVED
Wednesday, February 24, 2016EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, January 26, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 26, 2016PUBLISHED FOR OPPOSITION
Wednesday, January 6, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 15, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, December 14, 2015ASSIGNED TO EXAMINER
Tuesday, September 8, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, September 7, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

genvult preparations pharmaceutical treatment diseases disorders dysfunction vaccines system namely antifungal